This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Binimetinib

Dosage Form; Route: Tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 15 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: a. Advise females of reproductive potential to use effective contraception during treatment with binimetinib and for at least 30 days after the final dose of binimetinib. b. Exclude subjects with a history of serious retinopathy or retinal vein occlusion or any risk factors for serious retinopathy or retinal vein occlusion, including uncontrolled glaucoma or a history of hyperviscosity or hypercoagulability syndromes.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 15 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: See comments above

Analyte to measure (in appropriate biological fluid): Binimetinib in plasma

Bioequivalence based on (90% CI): Binimetinib

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.